At a glance
- Originator Roche
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Emphysema
Most Recent Events
- 24 Jan 2007 Discontinued for Emphysema in United Kingdom (unspecified route)
- 13 Feb 1996 No-Development-Reported for Emphysema in United Kingdom (unspecified route)